Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867178 | 0.94 | CTSV (0.41) | HRH3GSK3BCHRNA7AHRMTNR1A | |
| SCHEMBL6865687 | 0.93 | CTSV (0.43) | HRH3GSK3BCHRNA7AHRMTNR1A | |
| SCHEMBL6867285 | 0.89 | GSK3B (0.46) | GSK3BSIRT2SIRT1NPEPPSADORA3 | |
| SCHEMBL6991740 | 0.84 | GSK3B (0.44) | GSK3BSIRT2SIRT1NPEPPSADORA3 | |
| SCHEMBL6867603 | 0.84 | GSK3B (0.44) | GSK3BSIRT2SIRT1CTSVCTSL | |
| SCHEMBL6860151 | 0.83 | GSK3B (0.43) | GSK3BSIRT2SIRT1CTSVCTSL | |
| SCHEMBL6864924 | 0.83 | GSK3B (0.43) | GSK3BSIRT2SIRT1CTSVCTSL | |
| SCHEMBL6865292 | 0.83 | GSK3B (0.43) | GSK3BSIRT2SIRT1CTSVCTSL | |
| SCHEMBL7002332 | 0.83 | GSK3B (0.43) | GSK3BSIRT2SIRT1CTSVCTSL | |
| SCHEMBL6955651 | 0.75 | GSK3B (0.54) | GSK3BAHRSIRT2SIRT1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | HRH3 1571/4885GSK3B 92/4885CHRNA7 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.